Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
Author:
Affiliation:
1. Divisions of Hematology,
2. Hematopathology, and
3. Cytogenetics, Mayo Clinic, Rochester, MN; and
4. Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/118/17/4595/1463380/zh804311004595.pdf
Reference14 articles.
1. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.;Gangat;J Clin Oncol,2011
2. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.;Vaidya;Blood,2011
3. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.;Tam;J Clin Oncol,2009
4. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.;Caramazza;Leukemia,2011
5. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.;Morel;Blood,2010
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms;Scientific Reports;2024-02-02
2. Introduction on Stem Cell Therapy and Regeneration;Comprehensive Hematology and Stem Cell Research;2024
3. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms;2023-10-31
4. Myeloproliferative Neoplasms;Encyclopedia of Cell Biology;2023
5. Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies;Journal of Hematology;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3